ID   ITK_HUMAN               Reviewed;         620 AA.
AC   Q08881; B2R752; Q32ML7;
DT   01-OCT-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1994, sequence version 1.
DT   10-MAY-2017, entry version 188.
DE   RecName: Full=Tyrosine-protein kinase ITK/TSK;
DE            EC=2.7.10.2;
DE   AltName: Full=Interleukin-2-inducible T-cell kinase;
DE            Short=IL-2-inducible T-cell kinase;
DE   AltName: Full=Kinase EMT;
DE   AltName: Full=T-cell-specific kinase;
DE   AltName: Full=Tyrosine-protein kinase Lyk;
GN   Name=ITK; Synonyms=EMT, LYK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND INDUCTION.
RX   PubMed=8504851; DOI=10.1016/0014-5793(93)81520-A;
RA   Tanaka N., Asao H., Ohtani K., Nakamura M., Sugamura K.;
RT   "A novel human tyrosine kinase gene inducible in T cells by
RT   interleukin 2.";
RL   FEBS Lett. 324:1-5(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Thymus;
RX   PubMed=8364206;
RA   Gibson S., Leung B., Squire J.A., Hill M., Arima N., Goss P., Hogg D.,
RA   Mills G.B.;
RT   "Identification, cloning, and characterization of a novel human T-
RT   cell-specific tyrosine kinase located at the hematopoietin complex on
RT   chromosome 5q.";
RL   Blood 82:1561-1572(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 171-192, AND PHOSPHORYLATION AT TYR-180.
RX   PubMed=12573241; DOI=10.1016/S1570-9639(02)00524-1;
RA   Nore B.F., Mattsson P.T., Antonsson P., Backesjo C.-M., Westlund A.,
RA   Lennartsson J., Hansson H., Low P., Ronnstrand L., Smith C.I.E.;
RT   "Identification of phosphorylation sites within the SH3 domains of Tec
RT   family tyrosine kinases.";
RL   Biochim. Biophys. Acta 1645:123-132(2003).
RN   [7]
RP   PHOSPHORYLATION BY LCK.
RX   PubMed=9312162; DOI=10.1074/jbc.272.40.25401;
RA   Heyeck S.D., Wilcox H.M., Bunnell S.C., Berg L.J.;
RT   "Lck phosphorylates the activation loop tyrosine of the Itk kinase
RT   domain and activates Itk kinase activity.";
RL   J. Biol. Chem. 272:25401-25408(1997).
RN   [8]
RP   INDUCTION.
RX   PubMed=9701039; DOI=10.1093/intimm/10.7.1009;
RA   King P.D., Sadra A., Teng J.M., Bell G.M., Dupont B.;
RT   "CD2-mediated activation of the Tec-family tyrosine kinase ITK is
RT   controlled by proline-rich stretch-4 of the CD2 cytoplasmic tail.";
RL   Int. Immunol. 10:1009-1016(1998).
RN   [9]
RP   DOMAIN.
RX   PubMed=10795735; DOI=10.1016/S1074-7613(00)80189-2;
RA   Yang W.C., Collette Y., Nunes J.A., Olive D.;
RT   "Tec kinases: a family with multiple roles in immunity.";
RL   Immunity 12:373-382(2000).
RN   [10]
RP   FUNCTION IN PHOSPHORYLATION OF LAT.
RX   PubMed=12186560; DOI=10.1021/bi025554o;
RA   Perez-Villar J.J., Whitney G.S., Sitnick M.T., Dunn R.J.,
RA   Venkatesan S., O'Day K., Schieven G.L., Lin T.A., Kanner S.B.;
RT   "Phosphorylation of the linker for activation of T-cells by Itk
RT   promotes recruitment of Vav.";
RL   Biochemistry 41:10732-10740(2002).
RN   [11]
RP   FUNCTION.
RX   PubMed=12682224; DOI=10.4049/jimmunol.170.8.3971;
RA   Grasis J.A., Browne C.D., Tsoukas C.D.;
RT   "Inducible T cell tyrosine kinase regulates actin-dependent
RT   cytoskeletal events induced by the T cell antigen receptor.";
RL   J. Immunol. 170:3971-3976(2003).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites
RT   from human T cells using immobilized metal affinity chromatography and
RT   tandem mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [13]
RP   INTERACTION WITH PPIA/CYPA, AND MUTAGENESIS OF PRO-288.
RX   PubMed=15308100; DOI=10.1016/j.immuni.2004.07.005;
RA   Colgan J., Asmal M., Neagu M., Yu B., Schneidkraut J., Lee Y.,
RA   Sokolskaja E., Andreotti A., Luban J.;
RT   "Cyclophilin A regulates TCR signal strength in CD4+ T cells via a
RT   proline-directed conformational switch in Itk.";
RL   Immunity 21:189-201(2004).
RN   [14]
RP   INTERACTION WITH VAV1.
RX   PubMed=15661896; DOI=10.4049/jimmunol.174.3.1385;
RA   Dombroski D., Houghtling R.A., Labno C.M., Precht P., Takesono A.,
RA   Caplen N.J., Billadeau D.D., Wange R.L., Burkhardt J.K.,
RA   Schwartzberg P.L.;
RT   "Kinase-independent functions for Itk in TCR-induced regulation of Vav
RT   and the actin cytoskeleton.";
RL   J. Immunol. 174:1385-1392(2005).
RN   [15]
RP   SUBCELLULAR LOCATION.
RX   PubMed=17060314; DOI=10.1074/jbc.M609180200;
RA   Qi Q., Sahu N., August A.;
RT   "Tec kinase Itk forms membrane clusters specifically in the vicinity
RT   of recruiting receptors.";
RL   J. Biol. Chem. 281:38529-38534(2006).
RN   [16]
RP   INTERACTION WITH FASLG.
RX   PubMed=19807924; DOI=10.1186/1471-2172-10-53;
RA   Voss M., Lettau M., Janssen O.;
RT   "Identification of SH3 domain interaction partners of human FasL
RT   (CD178) by phage display screening.";
RL   BMC Immunol. 10:53-53(2009).
RN   [17]
RP   AUTOPHOSPHORYLATION.
RX   PubMed=19523959; DOI=10.1016/j.jmb.2009.06.023;
RA   Joseph R.E., Severin A., Min L., Fulton D.B., Andreotti A.H.;
RT   "SH2-dependent autophosphorylation within the Tec family kinase Itk.";
RL   J. Mol. Biol. 391:164-177(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-512 AND SER-565, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [19]
RP   UBIQUITINATION.
RX   PubMed=20596523; DOI=10.1371/journal.pone.0011332;
RA   Del Rincon S.V., Rogers J., Widschwendter M., Sun D., Sieburg H.B.,
RA   Spruck C.;
RT   "Development and validation of a method for profiling post-
RT   translational modification activities using protein microarrays.";
RL   PLoS ONE 5:E11332-E11332(2010).
RN   [20]
RP   FUNCTION IN PHOSPHORYLATION OF LCP2.
RX   PubMed=21725281; DOI=10.1038/emboj.2011.213;
RA   Sela M., Bogin Y., Beach D., Oellerich T., Lehne J.,
RA   Smith-Garvin J.E., Okumura M., Starosvetsky E., Kosoff R., Libman E.,
RA   Koretzky G., Kambayashi T., Urlaub H., Wienands J., Chernoff J.,
RA   Yablonski D.;
RT   "Sequential phosphorylation of SLP-76 at tyrosine 173 is required for
RT   activation of T and mast cells.";
RL   EMBO J. 30:3160-3172(2011).
RN   [21]
RP   STRUCTURE BY NMR OF 113-239.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the BTK motif and the SH3 domain of tyrosine-
RT   protein kinase ITK from human.";
RL   Submitted (OCT-2007) to the PDB data bank.
RN   [22]
RP   VARIANTS [LARGE SCALE ANALYSIS] LYS-19; LEU-23; GLN-451; TRP-581 AND
RP   ILE-587.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [23]
RP   VARIANT LPFS1 TRP-335, AND CHARACTERIZATION OF VARIANT LPSA1 TRP-335.
RX   PubMed=19425169; DOI=10.1172/JCI37901;
RA   Huck K., Feyen O., Niehues T., Rueschendorf F., Huebner N.,
RA   Laws H.-J., Telieps T., Knapp S., Wacker H.-H., Meindl A., Jumaa H.,
RA   Borkhardt A.;
RT   "Girls homozygous for an IL-2-inducible T cell kinase mutation that
RT   leads to protein deficiency develop fatal EBV-associated
RT   lymphoproliferation.";
RL   J. Clin. Invest. 119:1350-1358(2009).
CC   -!- FUNCTION: Tyrosine kinase that plays an essential role in
CC       regulation of the adaptive immune response. Regulates the
CC       development, function and differentiation of conventional T-cells
CC       and nonconventional NKT-cells. When antigen presenting cells (APC)
CC       activate T-cell receptor (TCR), a series of phosphorylation lead
CC       to the recruitment of ITK to the cell membrane, in the vicinity of
CC       the stimulated TCR receptor, where it is phosphorylated by LCK.
CC       Phosphorylation leads to ITK autophosphorylation and full
CC       activation. Once activated, phosphorylates PLCG1, leading to the
CC       activation of this lipase and subsequent cleavage of its
CC       substrates. In turn, the endoplasmic reticulum releases calcium in
CC       the cytoplasm and the nuclear activator of activated T-cells
CC       (NFAT) translocates into the nucleus to perform its
CC       transcriptional duty. Phosphorylates 2 essential adapter proteins:
CC       the linker for activation of T-cells/LAT protein and LCP2. Then, a
CC       large number of signaling molecules such as VAV1 are recruited and
CC       ultimately lead to lymphokine production, T-cell proliferation and
CC       differentiation. {ECO:0000269|PubMed:12186560,
CC       ECO:0000269|PubMed:12682224, ECO:0000269|PubMed:21725281}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC   -!- SUBUNIT: Homooligomerizes; this association negatively regulates
CC       kinase activity (By similarity). Interacts with PPIA/CYPA; this
CC       interaction regulates TCR signal strength via a proline-directed
CC       conformational switch in ITK. Interacts with THEMIS (By
CC       similarity). Interacts with FASLG. Interacts with VAV1; this
CC       interaction is important for VAV1 localization and TCR-induced
CC       actin polarization. {ECO:0000250, ECO:0000269|PubMed:15308100,
CC       ECO:0000269|PubMed:15661896, ECO:0000269|PubMed:19807924}.
CC   -!- INTERACTION:
CC       P04626:ERBB2; NbExp=2; IntAct=EBI-968552, EBI-641062;
CC       P48023:FASLG; NbExp=3; IntAct=EBI-968552, EBI-495538;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17060314}.
CC       Note=Localizes in the vicinity of cell surface receptors in the
CC       plasma membrane after receptor stimulation.
CC   -!- TISSUE SPECIFICITY: T-cell lines and natural killer cell lines.
CC   -!- INDUCTION: Through a myriad of surface receptors including the
CC       TCR/CD3 signaling complex, coreceptors, or chemokine receptors.
CC       {ECO:0000269|PubMed:8504851, ECO:0000269|PubMed:9701039}.
CC   -!- DOMAIN: The N-terminal PH domain allows ITK to be recruited to the
CC       plasma membrane by an activated PI3 kinase. This domain contains
CC       also a proline-rich region (PRR). The adjoining domain is a SH3
CC       domain, which binds to PRR (from itself or from other proteins).
CC       Next, a SH2 domain is required for binding tyrosine-phosphorylated
CC       substrates. In the C-terminal region, the kinase domain is
CC       required for tyrosine phosphorylation.
CC       {ECO:0000269|PubMed:10795735}.
CC   -!- PTM: Phosphorylated at Tyr-512 in the activation loop of the
CC       kinase domain by LCK. Subsequent autophosphorylation at Tyr-180
CC       leads to the kinase activation. The autophosphorylated Tyr-180
CC       lies within the substrate binding sequence of the SH3 domain.
CC       {ECO:0000269|PubMed:12573241, ECO:0000269|PubMed:9312162}.
CC   -!- PTM: Ubiquitinated. {ECO:0000269|PubMed:20596523}.
CC   -!- DISEASE: Lymphoproliferative syndrome 1 (LPFS1) [MIM:613011]: A
CC       rare immunodeficiency characterized by extreme susceptibility to
CC       infection with Epstein-Barr virus (EBV). Inadequate immune
CC       response to EBV can have a fatal outcome. Clinical features
CC       include splenomegaly, lymphadenopathy, anemia, thrombocytopenia,
CC       pancytopenia, recurrent infections. There is an increased risk for
CC       lymphoma. {ECO:0000269|PubMed:19425169}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. TEC subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ITKID43329ch5q33.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D13720; BAA02873.1; -; mRNA.
DR   EMBL; L10717; AAA36748.1; -; mRNA.
DR   EMBL; S65186; AAB28072.2; -; mRNA.
DR   EMBL; AK312846; BAG35699.1; -; mRNA.
DR   EMBL; CH471062; EAW61608.1; -; Genomic_DNA.
DR   EMBL; BC109077; AAI09078.1; -; mRNA.
DR   EMBL; BC109078; AAI09079.1; -; mRNA.
DR   CCDS; CCDS4336.1; -.
DR   PIR; S33253; S33253.
DR   RefSeq; NP_005537.3; NM_005546.3.
DR   UniGene; Hs.558348; -.
DR   PDB; 1SM2; X-ray; 2.30 A; A/B=357-620.
DR   PDB; 1SNU; X-ray; 2.50 A; A/B=357-620.
DR   PDB; 1SNX; X-ray; 3.20 A; A/B=357-620.
DR   PDB; 2E6I; NMR; -; A=113-169.
DR   PDB; 2LMJ; NMR; -; A=171-231.
DR   PDB; 2YUQ; NMR; -; A=162-239.
DR   PDB; 3MIY; X-ray; 1.67 A; A/B=357-620.
DR   PDB; 3MJ1; X-ray; 1.72 A; A=357-620.
DR   PDB; 3MJ2; X-ray; 1.90 A; A=357-620.
DR   PDB; 3QGW; X-ray; 2.10 A; A/B=357-620.
DR   PDB; 3QGY; X-ray; 2.10 A; A/B=357-620.
DR   PDB; 3T9T; X-ray; 1.65 A; A=354-620.
DR   PDB; 3V5J; X-ray; 2.59 A; A/B=357-620.
DR   PDB; 3V5L; X-ray; 1.86 A; A/B/C/D=357-620.
DR   PDB; 3V8T; X-ray; 2.00 A; A/B=357-620.
DR   PDB; 3V8W; X-ray; 2.27 A; A/B=357-620.
DR   PDB; 4HCT; X-ray; 1.48 A; A=354-620.
DR   PDB; 4HCU; X-ray; 1.43 A; A=354-620.
DR   PDB; 4HCV; X-ray; 1.48 A; A=354-620.
DR   PDB; 4KIO; X-ray; 2.18 A; A/B/C/D=357-620.
DR   PDB; 4L7S; X-ray; 2.03 A; A/B=357-620.
DR   PDB; 4M0Y; X-ray; 1.70 A; A=354-620.
DR   PDB; 4M0Z; X-ray; 2.00 A; A=354-620.
DR   PDB; 4M12; X-ray; 2.15 A; A=354-620.
DR   PDB; 4M13; X-ray; 1.85 A; A=354-620.
DR   PDB; 4M14; X-ray; 1.55 A; A=354-620.
DR   PDB; 4M15; X-ray; 1.52 A; A=354-620.
DR   PDB; 4MF0; X-ray; 2.67 A; A/B=357-620.
DR   PDB; 4MF1; X-ray; 2.11 A; A/B=357-620.
DR   PDB; 4PP9; X-ray; 2.58 A; A/B=357-620.
DR   PDB; 4PPA; X-ray; 2.67 A; A/B=357-620.
DR   PDB; 4PPB; X-ray; 2.82 A; A/B=357-620.
DR   PDB; 4PPC; X-ray; 2.95 A; A/B=357-620.
DR   PDB; 4PQN; X-ray; 1.71 A; A=357-620.
DR   PDB; 4QD6; X-ray; 2.45 A; A/B=357-620.
DR   PDB; 4RFM; X-ray; 2.10 A; A=357-620.
DR   PDBsum; 1SM2; -.
DR   PDBsum; 1SNU; -.
DR   PDBsum; 1SNX; -.
DR   PDBsum; 2E6I; -.
DR   PDBsum; 2LMJ; -.
DR   PDBsum; 2YUQ; -.
DR   PDBsum; 3MIY; -.
DR   PDBsum; 3MJ1; -.
DR   PDBsum; 3MJ2; -.
DR   PDBsum; 3QGW; -.
DR   PDBsum; 3QGY; -.
DR   PDBsum; 3T9T; -.
DR   PDBsum; 3V5J; -.
DR   PDBsum; 3V5L; -.
DR   PDBsum; 3V8T; -.
DR   PDBsum; 3V8W; -.
DR   PDBsum; 4HCT; -.
DR   PDBsum; 4HCU; -.
DR   PDBsum; 4HCV; -.
DR   PDBsum; 4KIO; -.
DR   PDBsum; 4L7S; -.
DR   PDBsum; 4M0Y; -.
DR   PDBsum; 4M0Z; -.
DR   PDBsum; 4M12; -.
DR   PDBsum; 4M13; -.
DR   PDBsum; 4M14; -.
DR   PDBsum; 4M15; -.
DR   PDBsum; 4MF0; -.
DR   PDBsum; 4MF1; -.
DR   PDBsum; 4PP9; -.
DR   PDBsum; 4PPA; -.
DR   PDBsum; 4PPB; -.
DR   PDBsum; 4PPC; -.
DR   PDBsum; 4PQN; -.
DR   PDBsum; 4QD6; -.
DR   PDBsum; 4RFM; -.
DR   ProteinModelPortal; Q08881; -.
DR   SMR; Q08881; -.
DR   BioGrid; 109907; 35.
DR   DIP; DIP-29974N; -.
DR   IntAct; Q08881; 12.
DR   MINT; MINT-110502; -.
DR   STRING; 9606.ENSP00000398655; -.
DR   BindingDB; Q08881; -.
DR   ChEMBL; CHEMBL2959; -.
DR   DrugBank; DB06589; Pazopanib.
DR   DrugBank; DB02010; Staurosporine.
DR   GuidetoPHARMACOLOGY; 2046; -.
DR   iPTMnet; Q08881; -.
DR   PhosphoSitePlus; Q08881; -.
DR   BioMuta; ITK; -.
DR   DMDM; 585361; -.
DR   MaxQB; Q08881; -.
DR   PaxDb; Q08881; -.
DR   PeptideAtlas; Q08881; -.
DR   PRIDE; Q08881; -.
DR   DNASU; 3702; -.
DR   Ensembl; ENST00000422843; ENSP00000398655; ENSG00000113263.
DR   GeneID; 3702; -.
DR   KEGG; hsa:3702; -.
DR   UCSC; uc003lwo.2; human.
DR   CTD; 3702; -.
DR   DisGeNET; 3702; -.
DR   GeneCards; ITK; -.
DR   HGNC; HGNC:6171; ITK.
DR   MalaCards; ITK; -.
DR   MIM; 186973; gene.
DR   MIM; 613011; phenotype.
DR   neXtProt; NX_Q08881; -.
DR   OpenTargets; ENSG00000113263; -.
DR   Orphanet; 238505; Autosomal recessive lymphoproliferative disease.
DR   PharmGKB; PA29968; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000119011; -.
DR   HOGENOM; HOG000233859; -.
DR   HOVERGEN; HBG008761; -.
DR   InParanoid; Q08881; -.
DR   KO; K07363; -.
DR   OMA; RTQRGLF; -.
DR   OrthoDB; EOG091G0D46; -.
DR   PhylomeDB; Q08881; -.
DR   TreeFam; TF351634; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-202433; Generation of second messenger molecules.
DR   Reactome; R-HSA-2871809; FCERI mediated Ca+2 mobilization.
DR   SignaLink; Q08881; -.
DR   SIGNOR; Q08881; -.
DR   ChiTaRS; ITK; human.
DR   EvolutionaryTrace; Q08881; -.
DR   GeneWiki; ITK_(gene); -.
DR   GenomeRNAi; 3702; -.
DR   PRO; PR:Q08881; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000113263; -.
DR   CleanEx; HS_ITK; -.
DR   ExpressionAtlas; Q08881; baseline and differential.
DR   Genevisible; Q08881; HS.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0007202; P:activation of phospholipase C activity; ISS:UniProtKB.
DR   GO; GO:0002250; P:adaptive immune response; ISS:UniProtKB.
DR   GO; GO:0006968; P:cellular defense response; TAS:ProtInc.
DR   GO; GO:0001816; P:cytokine production; ISS:UniProtKB.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0032609; P:interferon-gamma production; IEA:Ensembl.
DR   GO; GO:0032633; P:interleukin-4 production; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro.
DR   GO; GO:0001865; P:NK T cell differentiation; IBA:GO_Central.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IBA:GO_Central.
DR   GO; GO:0042127; P:regulation of cell proliferation; IBA:GO_Central.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0042110; P:T cell activation; TAS:UniProtKB.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR011993; PH_dom-like.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR001562; Znf_Btk_motif.
DR   Pfam; PF00779; BTK; 1.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00107; BTK; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF50729; SSF50729; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
DR   PROSITE; PS51113; ZF_BTK; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; ATP-binding; Complete proteome;
KW   Cytoplasm; Direct protein sequencing; Disease mutation; Immunity;
KW   Kinase; Metal-binding; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; SH2 domain; SH3 domain; Transferase;
KW   Tyrosine-protein kinase; Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN         1    620       Tyrosine-protein kinase ITK/TSK.
FT                                /FTId=PRO_0000088106.
FT   DOMAIN        4    111       PH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   DOMAIN      171    231       SH3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00192}.
FT   DOMAIN      239    338       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      363    615       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ZN_FING     113    149       Btk-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00432}.
FT   NP_BIND     369    377       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    482    482       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   METAL       121    121       Zinc. {ECO:0000250}.
FT   METAL       132    132       Zinc. {ECO:0000250}.
FT   METAL       133    133       Zinc. {ECO:0000250}.
FT   METAL       143    143       Zinc. {ECO:0000250}.
FT   BINDING     391    391       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     180    180       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12573241}.
FT   MOD_RES     512    512       Phosphotyrosine; by LCK.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     565    565       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   VARIANT      19     19       R -> K (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041710.
FT   VARIANT      23     23       P -> L (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041711.
FT   VARIANT     193    193       R -> Q (in dbSNP:rs17054374).
FT                                /FTId=VAR_051696.
FT   VARIANT     335    335       R -> W (in LPFS1; shows nearly
FT                                undetectable mutant ITK protein
FT                                consistent with severe protein
FT                                instability; dbSNP:rs121908191).
FT                                {ECO:0000269|PubMed:19425169}.
FT                                /FTId=VAR_063424.
FT   VARIANT     451    451       R -> Q (in a gastric adenocarcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs779372373).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041712.
FT   VARIANT     581    581       R -> W (in dbSNP:rs34482255).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041713.
FT   VARIANT     587    587       V -> I (in dbSNP:rs56005928).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041714.
FT   MUTAGEN     288    288       P->G: Complete loss of interaction with
FT                                PPIA/CYPA. {ECO:0000269|PubMed:15308100}.
FT   CONFLICT    171    172       PE -> GS (in Ref. 6; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    331    331       V -> W (in Ref. 2; AAB28072).
FT                                {ECO:0000305}.
FT   STRAND      127    133       {ECO:0000244|PDB:2E6I}.
FT   STRAND      148    152       {ECO:0000244|PDB:2E6I}.
FT   STRAND      171    173       {ECO:0000244|PDB:2YUQ}.
FT   STRAND      175    180       {ECO:0000244|PDB:2LMJ}.
FT   STRAND      187    189       {ECO:0000244|PDB:2YUQ}.
FT   STRAND      197    205       {ECO:0000244|PDB:2LMJ}.
FT   STRAND      208    212       {ECO:0000244|PDB:2LMJ}.
FT   STRAND      214    216       {ECO:0000244|PDB:2LMJ}.
FT   STRAND      218    221       {ECO:0000244|PDB:2LMJ}.
FT   HELIX       223    225       {ECO:0000244|PDB:2LMJ}.
FT   STRAND      226    228       {ECO:0000244|PDB:2LMJ}.
FT   HELIX       360    362       {ECO:0000244|PDB:4HCU}.
FT   STRAND      363    371       {ECO:0000244|PDB:4HCU}.
FT   STRAND      373    375       {ECO:0000244|PDB:4KIO}.
FT   STRAND      376    382       {ECO:0000244|PDB:4HCU}.
FT   TURN        383    385       {ECO:0000244|PDB:4HCU}.
FT   STRAND      386    393       {ECO:0000244|PDB:4HCU}.
FT   TURN        395    397       {ECO:0000244|PDB:3T9T}.
FT   HELIX       400    411       {ECO:0000244|PDB:4HCU}.
FT   STRAND      421    425       {ECO:0000244|PDB:4HCU}.
FT   STRAND      427    436       {ECO:0000244|PDB:4HCU}.
FT   HELIX       443    448       {ECO:0000244|PDB:4HCU}.
FT   TURN        449    452       {ECO:0000244|PDB:4HCU}.
FT   HELIX       456    475       {ECO:0000244|PDB:4HCU}.
FT   HELIX       485    487       {ECO:0000244|PDB:4HCU}.
FT   STRAND      488    490       {ECO:0000244|PDB:4HCU}.
FT   HELIX       492    494       {ECO:0000244|PDB:4HCU}.
FT   STRAND      496    498       {ECO:0000244|PDB:4HCU}.
FT   HELIX       503    506       {ECO:0000244|PDB:4HCU}.
FT   HELIX       510    513       {ECO:0000244|PDB:4HCU}.
FT   HELIX       522    524       {ECO:0000244|PDB:4HCU}.
FT   HELIX       527    532       {ECO:0000244|PDB:4HCU}.
FT   HELIX       537    552       {ECO:0000244|PDB:4HCU}.
FT   TURN        553    555       {ECO:0000244|PDB:4PQN}.
FT   TURN        558    561       {ECO:0000244|PDB:4HCU}.
FT   HELIX       564    572       {ECO:0000244|PDB:4HCU}.
FT   STRAND      581    583       {ECO:0000244|PDB:3V8W}.
FT   HELIX       585    594       {ECO:0000244|PDB:4HCU}.
FT   HELIX       599    601       {ECO:0000244|PDB:4HCU}.
FT   HELIX       605    617       {ECO:0000244|PDB:4HCU}.
SQ   SEQUENCE   620 AA;  71831 MW;  DAE396BD2309319D CRC64;
     MNNFILLEEQ LIKKSQQKRR TSPSNFKVRF FVLTKASLAY FEDRHGKKRT LKGSIELSRI
     KCVEIVKSDI SIPCHYKYPF QVVHDNYLLY VFAPDRESRQ RWVLALKEET RNNNSLVPKY
     HPNFWMDGKW RCCSQLEKLA TGCAQYDPTK NASKKPLPPT PEDNRRPLWE PEETVVIALY
     DYQTNDPQEL ALRRNEEYCL LDSSEIHWWR VQDRNGHEGY VPSSYLVEKS PNNLETYEWY
     NKSISRDKAE KLLLDTGKEG AFMVRDSRTA GTYTVSVFTK AVVSENNPCI KHYHIKETND
     NPKRYYVAEK YVFDSIPLLI NYHQHNGGGL VTRLRYPVCF GRQKAPVTAG LRYGKWVIDP
     SELTFVQEIG SGQFGLVHLG YWLNKDKVAI KTIREGAMSE EDFIEEAEVM MKLSHPKLVQ
     LYGVCLEQAP ICLVFEFMEH GCLSDYLRTQ RGLFAAETLL GMCLDVCEGM AYLEEACVIH
     RDLAARNCLV GENQVIKVSD FGMTRFVLDD QYTSSTGTKF PVKWASPEVF SFSRYSSKSD
     VWSFGVLMWE VFSEGKIPYE NRSNSEVVED ISTGFRLYKP RLASTHVYQI MNHCWKERPE
     DRPAFSRLLR QLAEIAESGL
//
